The inhibitions of some DDR molecules, such as CHK1 (checkpoint kinase 1) and ATR, have been demonstrated to enhance the effect of GEM in resistant pancreatic cancers [16,17]. This evidence concerns the gene ATR and pancreatic neoplasm.